digestive-diseases-2016_scientifictracks-abstracts

Volume 6, Issue 8(Suppl)

J Gastrointest Dig Syst 2016

ISSN:2161-069X JGDS, an open access journal

Page 46

Notes:

Digestive Diseases 2016

December 08-09, 2016

conferenceseries

.com

Digestive Diseases

December 08-09, 2016 Dubai, UAE

International Conference on

Impact of hepatic steatosis on response to antiviral therapy in Egyptian patients with chronic hepatitis-C

Emad Salem

Mansoura General Hospital, Egypt

Background & Aim:

Hepatic steatosis in hepatitis C virus (HCV) infected patients have been shown to enhance the progression of

liver fibrosis and decrease the response to antiviral therapy. The current study is designed to investigate the impact of hepatic steatosis

on the outcome of pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C genotype 4.

Patients & Methods:

A total number of 200 patients were selected from 270 patients who were referred to HCV Treatment Unit of

New Mansoura General Hospital from February 2012 to August 2013 after taking an informed consent. There were 129 males and

71 females with their ages ranged from 25 to 55 years (mean value, 35.5±15.2). They had proven chronic hepatitis C virus based on

history of exposure, clinical manifestations, positive anti-HCV antibody, positive HCV viremia and liver biopsy findings suggestive

of chronic hepatitis C.

Results:

Group I included 100 patients (70 men and 30 women; mean age of 42.912 years) without liver steatosis. Group II included

100 patients (59 men and 41 women; mean age of 45.2311 years) with liver steatosis. In terms of steatosis grading using the NAS

and METAVIR scoring systems, 50% had no steatosis while 8.5% had mild steatosis, 18.5% had moderate steatosis and 23% had

severe steatosis. Body mass index of patients receiving interferon is significant between both groups. Hepatomegaly shows significant

values between both groups. Platelets count, ALT, AST, s-cholesterol and s-triglycerides levels has statistically significant differences

between group I (non-steatotic) and group II (steatotic). There is statistically significant difference between both groups on necro-

inflammatory activity grades, high statistical significant difference between grading of steatosis and necro-inflammation and between

grading of steatosis and fibrosis stages. Statistical significance difference between both groups at SVR and steatosis has a negative

effect on SVR by comparison to non-steatotic group. High degree of hepatic steatosis has a negative impact on pegylated interferon

and ribavirin therapy in chronic HCV genotype 4 minimizing sustained virological response of rates.

Conclusion:

Our study confirms that hepatic steatosis correlates with BMI, s-cholesterol, s-triglycerides, fibrosis, necro-inflammatory

stages and has a negative impact on response to antiviral therapy.

Biography

Emad Salem is currently working in Hepatology Unit, Mansoura General Hospital, Egypt.

Emad Salem, J Gastrointest Dig Syst 2016, 6:8(Suppl)